drugset / Trial / NCT00391560
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II trial designed to determine the efficacy and safety of perifosine in patients with leukemia who develop progressive disease or recurrence while receiving therapy.
Timeline
- Start
- 2006-10
- Primary completion
- 2010-10
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Perifosine | Small molecule | 150 mg | Oral |